Cargando…

Cerebrospinal fluid levels of fatty acid–binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals

INTRODUCTION: Fatty acid–binding protein 3 (FABP3) is a biomarker of neuronal membrane disruption, associated with lipid dyshomeostasis—a notable Alzheimer's disease (AD) pathophysiological change. We assessed the association of cerebrospinal fluid (CSF) FABP3 levels with brain amyloidosis and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dhiman, Kunal, Villemagne, Victor L., Fowler, Christopher, Bourgeat, Pierrick, Li, Qiao‐Xin, Collins, Steven, Rowe, Christopher C., Masters, Colin L., Ames, David, Blennow, Kaj, Zetterberg, Henrik, Martins, Ralph N., Gupta, Veer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719998/ https://www.ncbi.nlm.nih.gov/pubmed/36479019 http://dx.doi.org/10.1002/dad2.12377

Ejemplares similares

Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study
por: Dhiman, Kunal, et al.
Publicado: (2022)

Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease
por: Dhiman, Kunal, et al.
Publicado: (2020)

Core Alzheimer’s disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods
por: Doecke, James D., et al.
Publicado: (2021)

Higher Coffee Consumption Is Associated With Slower Cognitive Decline and Less Cerebral Aβ-Amyloid Accumulation Over 126 Months: Data From the Australian Imaging, Biomarkers, and Lifestyle Study
por: Gardener, Samantha L., et al.
Publicado: (2021)

Rates of regional tau accumulation in ageing and across the Alzheimer's disease continuum: an AIBL (18)F-MK6240 PET study
por: Krishnadas, Natasha, et al.
Publicado: (2023)

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Alzheimer’s Amyloidopathy: An Alternative Aspect
por: Regland, Björn, et al.
Publicado: (2019)

Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score
por: Lim, Yen Ying, et al.
Publicado: (2015)

MR-Less Surface-Based Amyloid Assessment Based on (11)C PiB PET
por: Zhou, Luping, et al.
Publicado: (2014)

Relationship between amyloid and tau levels and its impact on tau spreading
por: Doré, Vincent, et al.
Publicado: (2021)

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples
por: Skillbäck, Tobias, et al.
Publicado: (2013)

Extracellular fluid, cerebrospinal fluid and plasma biomarkers of axonal and neuronal injury following intracerebral hemorrhage
por: Tobieson, Lovisa, et al.
Publicado: (2021)

Effect of BDNF Val66Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimer’s Disease: A Preliminary Study
por: Lim, Yen Ying, et al.
Publicado: (2014)

Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS
por: Hölttä, Mikko, et al.
Publicado: (2012)

Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease
por: Hall, Sara, et al.
Publicado: (2016)

Oxidative stress: culprit or consequence in Alzheimer’s amyloidopathy
por: Sharma, Chanchal, et al.
Publicado: (2023)

Plasma Glial Fibrillary Acidic Protein Is Associated with (18)F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer’s Disease
por: Chatterjee, Pratishtha, et al.
Publicado: (2023)

Imbalance in the response of pre- and post-synaptic components to amyloidopathy
por: Stephen, Terri-Leigh, et al.
Publicado: (2019)

A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study
por: Villemagne, Victor L., et al.
Publicado: (2017)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus
por: Tyrberg, Tobias, et al.
Publicado: (2020)

Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer’s Disease: A Pilot Study
por: Thordardottir, Steinunn, et al.
Publicado: (2020)

Mesial temporal tau in amyloid-β-negative cognitively normal older persons
por: Krishnadas, Natasha, et al.
Publicado: (2022)

Cognitive impairment without altered levels of cerebrospinal fluid biomarkers in patients with encephalitis caused by varicella-zoster virus: a pilot study
por: Eckerström, Marie, et al.
Publicado: (2020)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Growth differentiation factor 15 increases in both cerebrospinal fluid and serum during pregnancy
por: Andersson-Hall, Ulrika, et al.
Publicado: (2021)

Changes in serum and cerebrospinal fluid cytokines in response to non-neurological surgery: an observational study
por: Bromander, Sara, et al.
Publicado: (2012)

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
por: Sjödin, Simon, et al.
Publicado: (2017)

A universal neocortical mask for Centiloid quantification
por: Bourgeat, Pierrick, et al.
Publicado: (2023)

Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease
por: Niemelä, Valter, et al.
Publicado: (2018)

A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease
por: Ashton, Nicholas J., et al.
Publicado: (2019)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Molecular forms of neurogranin in cerebrospinal fluid
por: Nazir, Faisal Hayat, et al.
Publicado: (2020)

Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid
por: Selnes, Per, et al.
Publicado: (2010)

Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection
por: Bremell, Daniel, et al.
Publicado: (2013)

Cerebrospinal fluid monoamine metabolite profiles in bipolar disorder, ADHD, and controls
por: Pålsson, Erik, et al.
Publicado: (2017)

Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry
por: Sjödin, Simon, et al.
Publicado: (2016)

Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease
por: Rosén, Christoffer, et al.
Publicado: (2014)

Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders
por: Yilmaz, Aylin, et al.
Publicado: (2019)

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
por: Bjerke, Maria, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_3h9p36sgp3lh4uvi1209isbio2